# A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients

> **NCT06496971** · PHASE3 · RECRUITING · sponsor: **NaviFUS Corporation** · enrollment: 32 (estimated)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Glioblastoma Multiforme, Adult
- Glioma
- Brain Tumor
- Brain Tumor, Recurrent
- Neoplasms
- Neoplasms, Nerve Tissue

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Microbubble
- **DEVICE:** Low-Intensity Focused Ultrasound

## Key facts

- **NCT ID:** NCT06496971
- **Lead sponsor:** NaviFUS Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-08
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06496971

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06496971, "A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06496971. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*